Abstract

Liquid biopsy technologies have the potential to transform cancer patient management as it offers non-invasive diagnosis and real-time monitoring of disease progression and treatment responses. The use of liquid biopsy for non-invasive cancer diagnosis can have pivotal importance for the African continent where access to medical infrastructures is limited, as it eliminates the need for surgical biopsies. To apply liquid biopsy technologies in the African setting, the influence of environmental and population genetic factors must be known. In this review, we discuss the use of circulating tumor cells, cell-free nucleic acids, extracellular vesicles, protein, and other biomolecules in liquid biopsy technology for cancer management with special focus on African studies. We discussed the prospect, barriers, and other aspects that pose challenges to the use of liquid biopsy in the African continent.

Highlights

  • Cancer is a growing public health threat globally

  • Lung cancer had the highest incidence among males in 2018, with prostate cancer having the highest mortality burden among African men

  • This requires that more African-based studies are done to validate the applicability of circulating biomarkers and liquid biopsy technologies in diagnosis and treatment of cancer in Africa

Read more

Summary

Introduction

Cancer is a growing public health threat globally. GLOBOCAN 2018 data showed an overall increase in cancer cases worldwide with 18.1 million new cases and 9.6 million cancer deaths in. More cancers in Africa and Asia are related to infective pathogens than in other continents This requires that more African-based studies are done to validate the applicability of circulating biomarkers and liquid biopsy technologies in diagnosis and treatment of cancer in Africa. Tumor genetics, and epigenetic variations need to be explored and taken into account to identify population-specific cancer biomarkers in liquid biopsy adapted and optimized for diagnostic use in African countries. We aim at reviewing studies on the role of circulating tumor molecules in the diagnosis and treatment of cancer, with a particular focus in the African continent.

20 NHL patients
20 Inflammatory BC patients
Circulating Tumor Cells
Circulating Tumor DNA
Circulating Tumor RNAs
Circulating Coding RNA
Long Non-Coding RNAs
Circulating microRNAs
Exosomes
Circulating Proteins and Peptides
Challenges to Implementation of Liquid Biopsy Technology in Africa
Findings
The Prospect for Liquid Biopsy in Africa

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.